Positive News SentimentPositive NewsNASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $1.92 +0.06 (+2.95%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$1.82 -0.10 (-5.42%) As of 11/16/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Genelux Stock (NASDAQ:GNLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genelux alerts:Sign Up Key Stats Today's Range$1.86▼$2.0250-Day Range$1.82▼$2.6152-Week Range$1.77▼$5.89Volume277,009 shsAverage Volume422,710 shsMarket Capitalization$86.86 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform. Headquartered in Westlake Village, California, Genelux conducts research and clinical development of its therapies. Its work is focused on evaluating whether oncolytic viruses can offer new treatment options for people with cancer.AI Generated. May Contain Errors. Read More Genelux Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreGNLX MarketRank™: 3.18436499466 of 5 starsGenelux scored higher than 64% of companies evaluated by MarketBeat, and ranked 303rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingGenelux has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialGenelux has a consensus price target of $20.00, representing about 941.7% upside from its current price of $1.92.Amount of Analyst CoverageGenelux has only been the subject of 2 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Genelux are expected to grow in the coming year, from ($0.80) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 6.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.82% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 8.32.Change versus previous monthShort interest in Genelux has recently decreased by 2.44%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment1.82 News SentimentGenelux has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Genelux this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for GNLX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Genelux to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,320.00 in company stock.Percentage Held by Insiders7.50% of the stock of Genelux is held by insiders.Percentage Held by Institutions37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNLX Stock News HeadlinesGenelux Corporation Reports Third Quarter Financial Results and Provides Business UpdatesNovember 16 at 4:14 PM | globenewswire.comGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ...September 9, 2026 | markets.businessinsider.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapySeptember 9, 2026 | globenewswire.comGenelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung CancerAugust 13, 2026 | quiverquant.comQGenelux Corporation Reports Second Quarter Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comGenelux (GNLX) Stock Forecast & Price TargetJuly 11, 2026 | investing.comGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian CancerJune 30, 2026 | globenewswire.comSee More Headlines GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $4.36 at the beginning of 2026. Since then, GNLX shares have decreased by 56.0% and is now trading at $1.92. How were Genelux's earnings last quarter? Genelux Corporation (NASDAQ:GNLX) announced its quarterly earnings results on Monday, November, 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Genelux's top institutional investors include Woodward Diversified Capital LLC (5.26%), Marshall Wace LLP (0.22%), Trek Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.13%). Insiders that own company stock include Thomas Zindrick, Thomas Zindrick, Aladar Szalay, John Thomas, Yong Yu, John W Smither, Ralph Smalling, James L Tyree, Sean Ryder and Caroline Jewett. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genelux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include Cabaletta Bio (CABA), Gain Therapeutics (GANX), Unicycive Therapeutics (UNCY), Archer Aviation (ACHR), Aclaris Therapeutics (ACRS), Allogene Therapeutics (ALLO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/16/2026Today11/17/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GNLX's financial health is in the Red zone, according to TradeSmith. GNLX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GNLX CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees26Year Founded2001Price Target and Rating Average Price Target for Genelux$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+941.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.15 million Net MarginsN/A Pretax Margin-444,950.00% Return on Equity-205.85% Return on Assets-138.79% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual Sales$10 thousand Price / Sales8,686.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book6.40Miscellaneous Outstanding Shares45,240,000Free Float41,852,000Market Cap$86.86 million OptionableOptionable Beta0.68 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GNLX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.